Non-caloric sweetener provides magnetic resonance imaging contrast for cancer detection

Puneet Bagga, Mohammad Haris, Kevin D'Aquilla, Neil E. Wilson, Francesco M. Marincola, Mitchell D. Schnall, Hari Hariharan, Ravinder Reddy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Image contrast enhanced by exogenous contrast agents plays a crucial role in the early detection, characterization, and determination of the precise location of cancers. Here, we investigate the feasibility of using a non-nutritive sweetener, sucralose (commercial name, Splenda), as magnetic resonance imaging (MRI) contrast agent for cancer studies. Methods: High-resolution nuclear-magnetic-resonance spectroscopy and MR studies on sucralose solution phantom were performed to detect the chemical exchange saturation transfer (CEST) property of sucralose hydroxyl protons with bulk water (sucCEST). For the animal experiments, female Fisher rats (F344/NCR) were used to generate 9L-gliosarcoma model. MRI with CEST experiments were performed on anesthetized rats at 9.4 T MR scanner. Following the baseline CEST scans, sucralose solution was intravenously administered in control and tumor bearing rats. CEST acquisitions were continued during and following the administration of sucralose. Following the sucCEST, Gadolinium-diethylenetriamine pentaacetic acid was injected to perform Gd-enhanced imaging for visualizing the tumor. Results: The sucCEST contrast in vitro was found to correlate positively with the sucralose concentration and negatively with the pH, indicating the potential of this technique in cancer imaging. In a control animal, the CEST contrast from the brain was found to be unaffected following the administration of sucralose, demonstrating its blood-brain barrier impermeability. In a 9L glioma model, enhanced localized sucCEST contrast in the tumor region was detected while the unaffected brain region showed unaltered CEST effect implying the specificity of sucralose toward the tumorous tissue. The CEST asymmetry plots acquired from the tumor region before and after the sucralose infusion showed elevation of asymmetry at 1 ppm, pointing towards the role of sucralose in increased contrast. Conclusions: We show the feasibility of using sucralose and sucCEST in study of preclinical models of cancer. This study paves the way for the potential development of sucralose and other sucrose derivatives as contrast agents for clinical MRI applications.

Original languageEnglish
Article number119
JournalJournal of Translational Medicine
Volume15
Issue number1
DOIs
Publication statusPublished - 30 May 2017

Fingerprint

trichlorosucrose
Sweetening Agents
Magnetic resonance
Magnetic Resonance Imaging
Imaging techniques
Neoplasms
Tumors
Contrast Media
Rats
Non-Nutritive Sweeteners
Brain
Ion exchange
Animals
Bearings (structural)

Keywords

  • Cancer
  • CEST
  • Gadolinium
  • Glioma
  • MRI
  • Sucralose

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bagga, P., Haris, M., D'Aquilla, K., Wilson, N. E., Marincola, F. M., Schnall, M. D., ... Reddy, R. (2017). Non-caloric sweetener provides magnetic resonance imaging contrast for cancer detection. Journal of Translational Medicine, 15(1), [119]. https://doi.org/10.1186/s12967-017-1221-9

Non-caloric sweetener provides magnetic resonance imaging contrast for cancer detection. / Bagga, Puneet; Haris, Mohammad; D'Aquilla, Kevin; Wilson, Neil E.; Marincola, Francesco M.; Schnall, Mitchell D.; Hariharan, Hari; Reddy, Ravinder.

In: Journal of Translational Medicine, Vol. 15, No. 1, 119, 30.05.2017.

Research output: Contribution to journalArticle

Bagga, P, Haris, M, D'Aquilla, K, Wilson, NE, Marincola, FM, Schnall, MD, Hariharan, H & Reddy, R 2017, 'Non-caloric sweetener provides magnetic resonance imaging contrast for cancer detection', Journal of Translational Medicine, vol. 15, no. 1, 119. https://doi.org/10.1186/s12967-017-1221-9
Bagga, Puneet ; Haris, Mohammad ; D'Aquilla, Kevin ; Wilson, Neil E. ; Marincola, Francesco M. ; Schnall, Mitchell D. ; Hariharan, Hari ; Reddy, Ravinder. / Non-caloric sweetener provides magnetic resonance imaging contrast for cancer detection. In: Journal of Translational Medicine. 2017 ; Vol. 15, No. 1.
@article{c6867d42f900486397bbb15de8b91371,
title = "Non-caloric sweetener provides magnetic resonance imaging contrast for cancer detection",
abstract = "Background: Image contrast enhanced by exogenous contrast agents plays a crucial role in the early detection, characterization, and determination of the precise location of cancers. Here, we investigate the feasibility of using a non-nutritive sweetener, sucralose (commercial name, Splenda), as magnetic resonance imaging (MRI) contrast agent for cancer studies. Methods: High-resolution nuclear-magnetic-resonance spectroscopy and MR studies on sucralose solution phantom were performed to detect the chemical exchange saturation transfer (CEST) property of sucralose hydroxyl protons with bulk water (sucCEST). For the animal experiments, female Fisher rats (F344/NCR) were used to generate 9L-gliosarcoma model. MRI with CEST experiments were performed on anesthetized rats at 9.4 T MR scanner. Following the baseline CEST scans, sucralose solution was intravenously administered in control and tumor bearing rats. CEST acquisitions were continued during and following the administration of sucralose. Following the sucCEST, Gadolinium-diethylenetriamine pentaacetic acid was injected to perform Gd-enhanced imaging for visualizing the tumor. Results: The sucCEST contrast in vitro was found to correlate positively with the sucralose concentration and negatively with the pH, indicating the potential of this technique in cancer imaging. In a control animal, the CEST contrast from the brain was found to be unaffected following the administration of sucralose, demonstrating its blood-brain barrier impermeability. In a 9L glioma model, enhanced localized sucCEST contrast in the tumor region was detected while the unaffected brain region showed unaltered CEST effect implying the specificity of sucralose toward the tumorous tissue. The CEST asymmetry plots acquired from the tumor region before and after the sucralose infusion showed elevation of asymmetry at 1 ppm, pointing towards the role of sucralose in increased contrast. Conclusions: We show the feasibility of using sucralose and sucCEST in study of preclinical models of cancer. This study paves the way for the potential development of sucralose and other sucrose derivatives as contrast agents for clinical MRI applications.",
keywords = "Cancer, CEST, Gadolinium, Glioma, MRI, Sucralose",
author = "Puneet Bagga and Mohammad Haris and Kevin D'Aquilla and Wilson, {Neil E.} and Marincola, {Francesco M.} and Schnall, {Mitchell D.} and Hari Hariharan and Ravinder Reddy",
year = "2017",
month = "5",
day = "30",
doi = "10.1186/s12967-017-1221-9",
language = "English",
volume = "15",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Non-caloric sweetener provides magnetic resonance imaging contrast for cancer detection

AU - Bagga, Puneet

AU - Haris, Mohammad

AU - D'Aquilla, Kevin

AU - Wilson, Neil E.

AU - Marincola, Francesco M.

AU - Schnall, Mitchell D.

AU - Hariharan, Hari

AU - Reddy, Ravinder

PY - 2017/5/30

Y1 - 2017/5/30

N2 - Background: Image contrast enhanced by exogenous contrast agents plays a crucial role in the early detection, characterization, and determination of the precise location of cancers. Here, we investigate the feasibility of using a non-nutritive sweetener, sucralose (commercial name, Splenda), as magnetic resonance imaging (MRI) contrast agent for cancer studies. Methods: High-resolution nuclear-magnetic-resonance spectroscopy and MR studies on sucralose solution phantom were performed to detect the chemical exchange saturation transfer (CEST) property of sucralose hydroxyl protons with bulk water (sucCEST). For the animal experiments, female Fisher rats (F344/NCR) were used to generate 9L-gliosarcoma model. MRI with CEST experiments were performed on anesthetized rats at 9.4 T MR scanner. Following the baseline CEST scans, sucralose solution was intravenously administered in control and tumor bearing rats. CEST acquisitions were continued during and following the administration of sucralose. Following the sucCEST, Gadolinium-diethylenetriamine pentaacetic acid was injected to perform Gd-enhanced imaging for visualizing the tumor. Results: The sucCEST contrast in vitro was found to correlate positively with the sucralose concentration and negatively with the pH, indicating the potential of this technique in cancer imaging. In a control animal, the CEST contrast from the brain was found to be unaffected following the administration of sucralose, demonstrating its blood-brain barrier impermeability. In a 9L glioma model, enhanced localized sucCEST contrast in the tumor region was detected while the unaffected brain region showed unaltered CEST effect implying the specificity of sucralose toward the tumorous tissue. The CEST asymmetry plots acquired from the tumor region before and after the sucralose infusion showed elevation of asymmetry at 1 ppm, pointing towards the role of sucralose in increased contrast. Conclusions: We show the feasibility of using sucralose and sucCEST in study of preclinical models of cancer. This study paves the way for the potential development of sucralose and other sucrose derivatives as contrast agents for clinical MRI applications.

AB - Background: Image contrast enhanced by exogenous contrast agents plays a crucial role in the early detection, characterization, and determination of the precise location of cancers. Here, we investigate the feasibility of using a non-nutritive sweetener, sucralose (commercial name, Splenda), as magnetic resonance imaging (MRI) contrast agent for cancer studies. Methods: High-resolution nuclear-magnetic-resonance spectroscopy and MR studies on sucralose solution phantom were performed to detect the chemical exchange saturation transfer (CEST) property of sucralose hydroxyl protons with bulk water (sucCEST). For the animal experiments, female Fisher rats (F344/NCR) were used to generate 9L-gliosarcoma model. MRI with CEST experiments were performed on anesthetized rats at 9.4 T MR scanner. Following the baseline CEST scans, sucralose solution was intravenously administered in control and tumor bearing rats. CEST acquisitions were continued during and following the administration of sucralose. Following the sucCEST, Gadolinium-diethylenetriamine pentaacetic acid was injected to perform Gd-enhanced imaging for visualizing the tumor. Results: The sucCEST contrast in vitro was found to correlate positively with the sucralose concentration and negatively with the pH, indicating the potential of this technique in cancer imaging. In a control animal, the CEST contrast from the brain was found to be unaffected following the administration of sucralose, demonstrating its blood-brain barrier impermeability. In a 9L glioma model, enhanced localized sucCEST contrast in the tumor region was detected while the unaffected brain region showed unaltered CEST effect implying the specificity of sucralose toward the tumorous tissue. The CEST asymmetry plots acquired from the tumor region before and after the sucralose infusion showed elevation of asymmetry at 1 ppm, pointing towards the role of sucralose in increased contrast. Conclusions: We show the feasibility of using sucralose and sucCEST in study of preclinical models of cancer. This study paves the way for the potential development of sucralose and other sucrose derivatives as contrast agents for clinical MRI applications.

KW - Cancer

KW - CEST

KW - Gadolinium

KW - Glioma

KW - MRI

KW - Sucralose

UR - http://www.scopus.com/inward/record.url?scp=85019696878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019696878&partnerID=8YFLogxK

U2 - 10.1186/s12967-017-1221-9

DO - 10.1186/s12967-017-1221-9

M3 - Article

C2 - 28558795

AN - SCOPUS:85019696878

VL - 15

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 119

ER -